Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Current Liabilities (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Total Current Liabilities readings, the most recent being $3.3 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 3.24% to $3.3 million in Q1 2026 year-over-year; TTM through Jan 2026 was $3.3 million, a 3.24% decrease, with the full-year FY2025 number at $1.7 million, down 7.86% from a year prior.
  • Total Current Liabilities hit $3.3 million in Q1 2026 for Pharma-Bio Serv, up from $1.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $3.7 million in Q1 2024 to a low of $1.7 million in Q3 2025.
  • Median Total Current Liabilities over the past 5 years was $2.2 million (2022), compared with a mean of $2.3 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 58.05% in 2022 and later skyrocketed 87.53% in 2024.
  • Pharma-Bio Serv's Total Current Liabilities stood at $2.1 million in 2022, then rose by 2.18% to $2.2 million in 2023, then fell by 12.37% to $1.9 million in 2024, then fell by 7.86% to $1.7 million in 2025, then soared by 90.34% to $3.3 million in 2026.
  • The last three reported values for Total Current Liabilities were $3.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025) per Business Quant data.